Prestige Biopharma is one of the fastest growing biopharmaceuticals focusing on the development of biosimilars and first-in-class antibody drugs as well as vaccines for infectious diseases.
With decades of R&D and operational experience in drug discovery, we expedite future biologics development and commercialization in a concerted approach based on our proprietary technologies and scientific capabilities.
Prestige strives to become a global innovator through the development of first-in-class antibody therapeutics including PBP1510 anti-PAUF mAb for pancreatic cancer (INN-Ulenistamab) that recently obtained orphan designation from FDA, EMA and MFDS. Prestige’s rich portfolio of biosimilars in various stages including HD201 trastuzumab in EU EMA’s MAA review, HD204 bevacizumab in global Phase 3, PBP1502 adalimumab in Phase 1 and others, is aimed to provide affordable quality medicines to those who need. Prestige has expanded its business into development and manufacturing of vaccines through its global scale vaccine center, starting with partnered commercial production of COVID-19 vaccines.